MedTrace Logo

Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Diabetic Foot

NCT02538705 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2017-04-05

No results posted yet for this study

Summary

The purpose of this study is to determine whether pl-vegf165 (Neovasculgen) is effective in the treatment of ulcers related to diabetic foot syndrome

Conditions

  • Ulcers Related to Diabetic Foot Syndrome

Interventions

DRUG

Neovasculgen

Sponsors & Collaborators

  • Ryazan State Medical University

    collaborator OTHER

  • Vidnoe District Hospital

    collaborator UNKNOWN

  • Artgen Biotech

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-08-31
Primary Completion
2016-01-01
Completion
2016-01-01

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02538705 on ClinicalTrials.gov